Unlock Early Insights into Drug Discovery

Early-stage drug discovery requires a clear understanding of how candidate compounds impact cellular function before advancing to expensive downstream studies. Relying on a single biomarker often fails to capture the complexity of biological response. A broader, multiplexed approach to cell health biomarker analysis can provide deeper insight into compound activity, mechanism of action, and potential toxicity.

In cancer research and preclinical drug development, evaluating multiple biological pathways simultaneously, including inflammation, apoptosis, stress response, and cell signaling, helps researchers generate more predictive data earlier in the screening process. By analyzing 16 key biomarkers at once, scientists can gain a more complete picture of cellular health while conserving valuable samples.

This app note explores how multiplex biomarker profiling can strengthen early-stage screening strategies and support more confident decision-making in drug discovery workflows.

What You’ll Learn

• How multiplex analysis of 16 biomarkers enhances early-stage drug screening

• Why comprehensive cell health profiling improves cancer research insights

• How to generate high-content data while minimizing sample volume

Download the application note to discover how advanced cell health biomarker analysis can help streamline early-stage drug discovery and improve translational outcomes.